<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714504</url>
  </required_header>
  <id_info>
    <org_study_id>Fusarium prophylaxis</org_study_id>
    <nct_id>NCT02714504</nct_id>
  </id_info>
  <brief_title>Anti-mold Azole in the Prophylaxis for Invasive Fusariosis</brief_title>
  <acronym>Fusarproph</acronym>
  <official_title>Evaluation of the Efficacy of Anti-mold Azole Prophylaxis in High-risk Hematologic Patients With Baseline Superficial Skin Lesions Positive for Fusarium Spp</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients admitted for autologous or allogeneic hematopoietic cell transplantation,
      induction-remission chemotherapy for acute myeloid leukemia, myelodysplasia or acute lymphoid
      leukemia, or to receive immunosuppressive therapy for aplastic anemia will be screened with
      dermatologic examination. In the presence of any skin lesion in the extremities, direct exam
      and fungal culture will be performed. If these exams indicate the presence of Fusarium
      species, patients will receive anti-mold azole prophylaxis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients admitted for autologous or allogeneic hematopoietic cell transplantation,
      induction-remission chemotherapy for acute myeloid leukemia, myelodysplasia or acute lymphoid
      leukemia, or to receive immunosuppressive therapy for aplastic anemia will be screened on
      admission. Patients may be included more than once, provided that a new treatment is
      administered and &gt;30 days elapses from one to other admission (episode).

      Screening will consist of a thorough physical examination in the extremities. In case of a
      skin lesion, direct exam and fungal culture will be performed. Nail samples will be obtained
      by scrapping the nails with a curette, and samples from interdigital areas will be obtained
      using swabs.

      In a first phase no intervention will be performed. In a second phase, if direct exam and /or
      culture indicate the presence of Fusarium spp., primary antifungal therapy with an anti-mold
      azole (voriconazole (200 mg BID) or posaconazole (200 mg TID) will be started.

      Patients will be followed until discharge. The primary endpoint is invasive fusariosis,
      comparing the observational period with the intervention period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who develop invasive fusariosis until neutrophil recovery</measure>
    <time_frame>Until neutrophil recovery, for an average of 4 weeks</time_frame>
    <description>Proportion of patients who develop invasive fusariosis until neutrophil recovery, for an average of 4 weeks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">239</enrollment>
  <condition>Fusariosis</condition>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>observational</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No anti-mold prophylaxis given on the basis of results of baseline presence of skin lesions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-mold prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-mold prophylaxis with either voriconazole or posaconazole for patients with baseline skin lesions in the extremities positive for Fusarium spp.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole or posaconazole</intervention_name>
    <description>Azole with activity against molds</description>
    <arm_group_label>Anti-mold prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  admission for autologous or allogeneic hematopoietic cell transplantation,
             induction-remission chemotherapy for acute myeloid leukemia, myelodysplasia or acute
             lymphoid leukemia, or to receive immunosuppressive therapy for aplastic anemia

        Exclusion Criteria:

          -  prior documentation of invasive fusariosis or allergy to azoles
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Federal University of Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>March 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>March 18, 2016</last_update_submitted>
  <last_update_submitted_qc>March 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Rio de Janeiro</investigator_affiliation>
    <investigator_full_name>Marcio Nucci</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
    <mesh_term>Fusariosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>January 23, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

